Jacob D Soumerai

24PUBLICATIONS
111CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Mar 26, 2026
A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

Jennifer L Crombie, Christine E Ryan, Yue Ren

|Oct 31, 2025
A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

J Erika Haydu, Robert A Redd, Matthew M Lei

|Jul 15, 2025
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.

Leon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson

|Nov 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL.

Jacob D Soumerai, Jacqueline Barrientos, Inhye Ahn

Pageof 4

Frequent Collaborators

8 joint publications

Jeremy S Abramson

5 joint publications

Matthew M Lei

5 joint publications

Andrew D Zelenetz

4 joint publications

Jeffrey A Barnes